Skip to content

Epothakon Pharmaceuticals avoids prosecution after RBI compounding order

By News Analysis India · · 1 min read

The Enforcement Directorate concluded its inquiry into Epothakon Pharmaceuticals Private Ltd after the Reserve Bank of India sanctioned a compounding settlement for FEMA breaches. The firm paid Rs 40.52 lakh as directed, prompting the ED to terminate the case.

Investigators had found that the company delayed filing mandatory foreign exchange forms after receiving close to Rs 9.91 crore in overseas capital, and also postponed the FC‑GPR filing for almost Rs 30 crore. Shares were prematurely issued – Rs 18.48 lakh worth before the foreign money arrived and Rs 2.25 crore worth after the stipulated 180‑day period, both contrary to the regulations.

Additionally, three share allocations proceeded without the required clearance from the Government of India. The firm sought RBI’s permission to compound these violations under Section 15, and the ED supplied a No Objection Certificate, enabling the RBI to issue the compounding order on July 6, 2026.

According to the ED, when a violation qualifies for compounding and no other legal impediments exist, the agency issues an NOC. This approach is designed to foster voluntary compliance, cut down on court cases, and streamline business activities.